La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Amgen Résultats passés
Passé contrôle des critères 0/6
Amgen's earnings have been declining at an average annual rate of -7.1%, while the Biotechs industry saw earnings growing at 19.1% annually. Revenues have been growing at an average rate of 4.3% per year. Amgen's return on equity is 52.8%, and it has net margins of 10.1%.
Informations clés
-7.1%
Taux de croissance des bénéfices
-3.8%
Taux de croissance du BPA
| Biotechs Croissance de l'industrie | 17.0% |
| Taux de croissance des recettes | 4.3% |
| Rendement des fonds propres | 52.8% |
| Marge nette | 10.1% |
| Dernière mise à jour des bénéfices | 30 Jun 2024 |
Mises à jour récentes des performances passées
Recent updates
Amgen Inc. Just Missed EPS By 46%: Here's What Analysts Think Will Happen Next
Aug 09
Amgen: Shows Why Dividend Investing Is Getting Tougher
Aug 07Amgen (NASDAQ:AMGN) Takes On Some Risk With Its Use Of Debt
Jul 26The Price Is Right For Amgen Inc. (NASDAQ:AMGN)
Jul 11Amgen: An Emerging GLP-1 Play, Modest Mid-Teens P/E With Strong Momentum
Jul 05Amgen: You Haven't Seen Anything Yet
Jun 17Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card
Jun 04Amgen Stock: Poised To Break Out (Technical Analysis)
May 21Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?
May 04Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet
May 01Amgen: The Giant With An Impressive Pipeline
Apr 15Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Apr 01Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock
Mar 31Amgen Will Benefit From Increased Medical Spending
Mar 12Amgen: A Good Dividend Growth Stock For The Watch List
Mar 04Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit
Feb 21Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now
Feb 16Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable
Feb 08Amgen: Accelerating The Business And Dividend Growth
Jan 29Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?
Jan 29Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks
Jan 22Is Amgen (NASDAQ:AMGN) A Risky Investment?
Dec 28Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors
Dec 13Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?
Oct 23Is Amgen (NASDAQ:AMGN) Using Too Much Debt?
Sep 22Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?
Sep 04Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13
Aug 05Ventilation des recettes et des dépenses
Comment Amgen gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 30 Jun 24 | 30,934 | 3,130 | 7,207 | 5,374 |
| 31 Mar 24 | 29,532 | 3,763 | 6,716 | 5,040 |
| 31 Dec 23 | 28,190 | 6,717 | 6,166 | 4,755 |
| 30 Sep 23 | 26,833 | 7,566 | 5,464 | 4,574 |
| 30 Jun 23 | 26,582 | 7,979 | 5,411 | 4,607 |
| 31 Mar 23 | 26,190 | 7,917 | 5,444 | 4,533 |
| 31 Dec 22 | 26,323 | 6,552 | 5,414 | 4,434 |
| 30 Sep 22 | 26,330 | 6,835 | 5,267 | 4,458 |
| 30 Jun 22 | 26,384 | 6,576 | 5,285 | 4,768 |
| 31 Mar 22 | 26,316 | 5,723 | 5,342 | 4,811 |
| 31 Dec 21 | 25,979 | 5,893 | 5,368 | 4,819 |
| 30 Sep 21 | 25,767 | 5,609 | 5,716 | 4,700 |
| 30 Jun 21 | 25,484 | 5,746 | 5,757 | 4,340 |
| 31 Mar 21 | 25,164 | 7,085 | 5,668 | 4,222 |
| 31 Dec 20 | 25,424 | 7,264 | 5,730 | 4,207 |
| 30 Sep 20 | 24,987 | 7,352 | 5,470 | 4,290 |
| 30 Jun 20 | 24,301 | 7,299 | 5,347 | 4,229 |
| 31 Mar 20 | 23,966 | 7,675 | 5,312 | 4,189 |
| 31 Dec 19 | 23,362 | 7,842 | 5,150 | 4,116 |
| 30 Sep 19 | 23,395 | 8,067 | 5,196 | 3,986 |
| 30 Jun 19 | 23,562 | 7,958 | 5,266 | 3,911 |
| 31 Mar 19 | 23,750 | 8,075 | 5,359 | 3,856 |
| 31 Dec 18 | 23,747 | 8,394 | 5,332 | 3,737 |
| 30 Sep 18 | 23,319 | 2,202 | 5,268 | 3,598 |
| 30 Jun 18 | 23,188 | 2,364 | 5,145 | 3,549 |
| 31 Mar 18 | 22,939 | 2,219 | 5,001 | 3,553 |
| 31 Dec 17 | 22,849 | 1,979 | 4,870 | 3,562 |
| 30 Sep 17 | 23,012 | 8,178 | 4,824 | 3,597 |
| 30 Jun 17 | 23,050 | 8,174 | 4,898 | 3,710 |
| 31 Mar 17 | 22,928 | 7,893 | 4,981 | 3,737 |
| 31 Dec 16 | 22,991 | 7,722 | 5,120 | 3,840 |
| 30 Sep 16 | 22,562 | 7,587 | 5,164 | 3,791 |
| 30 Jun 16 | 22,474 | 7,433 | 5,164 | 3,920 |
| 31 Mar 16 | 22,156 | 7,216 | 5,032 | 3,984 |
| 31 Dec 15 | 21,662 | 6,939 | 4,855 | 4,006 |
| 30 Sep 15 | 21,457 | 6,433 | 4,778 | 4,162 |
| 30 Jun 15 | 20,765 | 5,814 | 4,747 | 4,061 |
| 31 Mar 15 | 20,575 | 5,708 | 4,723 | 4,115 |
| 31 Dec 14 | 20,063 | 5,158 | 4,720 | 4,248 |
| 30 Sep 14 | 19,743 | 4,885 | 4,851 | 4,312 |
| 30 Jun 14 | 19,460 | 5,009 | 4,887 | 4,283 |
| 31 Mar 14 | 18,959 | 4,720 | 5,007 | 4,232 |
| 31 Dec 13 | 18,676 | 5,081 | 5,142 | 4,083 |
| 30 Sep 13 | 17,980 | 4,848 | 5,012 | 3,772 |
Des revenus de qualité: AMGN has a large one-off gain of $1.0B impacting its last 12 months of financial results to 30th June, 2024.
Augmentation de la marge bénéficiaire: AMGN's current net profit margins (10.1%) are lower than last year (30%).
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: AMGN's earnings have declined by 7.1% per year over the past 5 years.
Accélération de la croissance: AMGN's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Bénéfices par rapport au secteur d'activité: AMGN had negative earnings growth (-60.8%) over the past year, making it difficult to compare to the Biotechs industry average (0.5%).
Rendement des fonds propres
ROE élevé: Whilst AMGN's Return on Equity (52.83%) is outstanding, this metric is skewed due to their high level of debt.